Retigabine (INN) or ezogabine (USAN) codenamed D-23129 is an anticonvulsant used as a treatment for partial epilepsies. The drug was developed by Valeant Pharmaceuticals and GlaxoSmithKline. It was approved by the European Medicines Agency under the trade name Trobalt® on March 28 2011 and by the United States Food and Drug Administration (FDA) under the trade name Potiga on June 10 2010.
This page contains content from the copyrighted Wikipedia article "Retigabine"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
